{"id":"W2023205599","doi":"10.1111/epi.12643","title":"Long‐term safety of perampanel and seizure outcomes in refractory partial‐onset seizures and secondarily generalized seizures: Results from phase <scp>III</scp> extension study 307","year":2014,"lang":"en","type":"article","venue":"Epilepsia","topic":"Epilepsy research and treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"Cilag; Johnson and Johnson; UCB Pharma; Sun Pharma; H. Lundbeck A/S; Eisai; Pfizer; Ministero della Salute; National Institutes of Health; Upsher-Smith; Innovation and Technology Fund; Vertex Pharmaceuticals; Medichem; Agenzia Italiana del Farmaco, Ministero della Salute; Sunovion; European Commission; Sanofi; University of Melbourne; GlaxoSmithKline; Health and Health Services Research Fund; Royal Melbourne Hospital Neuroscience Foundation","keywords":"Irritability; Perampanel; Discontinuation; Somnolence; Tolerability; Medicine; Epilepsy; Adverse effect; Convulsion; Anesthesia; Pediatrics; Internal medicine; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002677073,0.0003942062,0.001151314,0.0001537817,0.000195075,0.0004224583,0.0003076222,0.0004724897,0.001188751],"category_scores_gemma":[0.001404159,0.0001401844,0.001005492,0.0002595549,0.0002662866,0.0004438726,0.0002681035,0.0009663118,0.0003637383],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004608795,"about_ca_system_score_gemma":0.0008405505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000642657,"about_ca_topic_score_gemma":0.001609189,"domain_scores_codex":[0.9993126,0.0003345651,0.00009633546,0.00007726198,0.0001087723,0.00007041663],"domain_scores_gemma":[0.9979824,0.0003562746,0.000904383,0.000197658,0.0002383746,0.0003208694],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5251964,0.01440601,0.2248274,0.001719585,0.004665,0.0008908201,0.0006105234,0.001825898,0.05525888,0.0001053208,0.003805182,0.1666891],"study_design_scores_gemma":[0.1066077,0.2824638,0.5949609,0.0001602691,0.002176514,0.002150945,0.0001653254,0.0009655237,0.006461753,0.0001496025,0.003677893,0.000059778],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978612,0.0009145163,0.0001033287,0.00006207961,0.000008458383,0.0001405914,0.0005250223,0.00001011936,0.0003746873],"genre_scores_gemma":[0.9975227,0.0004573707,0.0001607964,0.0001330417,0.00002688136,0.0001360542,0.00129397,0.000005295713,0.0002638901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002677073,"threshold_uncertainty_score":0.01415783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02865429529973181,"score_gpt":0.3297866609927779,"score_spread":0.3011323656930461,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}